• Profit before tax expected to be ~$10.9M, up 122% vs pcp
• Total revenue expected to be ~$93.6M, up 18% vs pcp
• Gross margin expected to be ~78.5%, down from 79.7% in pcp

Nanosonics Limited, a leader in infection prevention solutions, has provided a trading update for the first half of the 2025 financial year (H1 FY25). The company's preliminary unaudited results based on management accounts show that profit before tax for the half is expected to be approximately $10.9 million, compared to $4.9 million in the prior corresponding period (pcp) and $8.1 million in H2 FY24. Total revenue for the half is anticipated to be approximately $93.6 million, up 18% (18% in constant currency) from $79.6 million in the pcp and up 4% from $90.4 million in H2 FY24. Gross margin for the half is expected to be approximately 78.5%, compared with 79.7% in the pcp and 76.3% in H2 FY24. Operating expenses for the half are expected to be approximately $66.7 million, up 10% from the pcp and up 3% on H2 FY24. The company's CEO and President, Michael Kavanagh, attributed the revenue growth to a 20% increase in consumables and service annuity revenue streams compared to the pcp. The total number of trophon units sold in the first half was broadly in line with internal forecasts and similar to the pcp, with overall capital revenue up 11% compared to the pcp. The company expects to achieve revenue, gross margin, and operating expenses in FY25 around the top of the ranges specified in its FY25 outlook statement, assuming an AUD/USD exchange rate of 0.67.

Nanosonics currently expects to achieve revenue, gross margin and operating expenses in FY25 around the top of each of the ranges for those measures specified in Nanosonics' FY25 outlook statement (assuming a AUD/USD exchange rate of 0.67).